Association between gastrin-releasing peptide receptor expression as assessed with [68Ga]Ga-RM2 PET/CT and histopathological tumor regression after neoadjuvant chemotherapy in primary breast cancer

2020 ◽  
Vol 86-87 ◽  
pp. 37-43
Author(s):  
Kerstin Michalski ◽  
Christian Stoykow ◽  
Peter Bronsert ◽  
Ingolf Juhasz-Böss ◽  
Philipp T. Meyer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Primary Breast Cancer ◽  
Tumor Regression ◽  
Receptor Expression ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Pet Ct

Micro-imaging characterization of mouse models of metastasis

2005 ◽  
Author(s):  
◽  
Christopher Todd Winkelmann
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Mouse Models ◽  
Bone Lesion ◽  
Receptor Expression ◽  
Bone Lesions ◽  
Micro Ct ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Models Of Disease

[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] Non-invasive imaging techniques have been recently developed to characterize animal models of disease. The overarching hypothesis of this work explores the use of three micro-imaging modalities, including Micro-CT, PET and SPECT, to characterize tumor anatomical progression, metabolism, bone lesion remodeling, and/or gastrin releasing peptide receptor expression in mouse models of metastatic melanoma and prostate and breast cancer bone metastasis. Micro-CT was shown to provide excellent anatomical information about tumor progression in several different tissues including lung, bone, and subcutaneous tissues. Micro-PET imaging demonstrated increased tumor metabolism in melanoma tumors, but was not able to discern bone remodeling in breast cancer bone lesions. Micro-SPECT imaging demonstrated gastrin-releasing peptide receptor expression in a prostate cancer bone metastasis model. The results from this work demonstrate the ability of micro-imaging technologies to non-invasively probe mouse models of disease to obtain information in vivo that is not possible with ex vivo experimental techniques.

scholarly journals 0173 Predictive value of 18F-FDG PET-CT in primary breast cancer patients receiving neoadjuvant chemotherapy

The Breast ◽  
2009 ◽  
Vol 18 ◽  
pp. S61-S62
Author(s):  
J.W.H. Tsang ◽  
D. Yeung ◽  
A.C.Y. Chan ◽  
C.H.N. Wong ◽  
L.W.S. Leung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Predictive Value ◽  
Fdg Pet ◽  
Primary Breast Cancer ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Gastrin-Releasing Peptide Receptor Antagonist [68Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6106
Author(s):  
Kerstin Michalski ◽  
Lars Kemna ◽  
Jasmin Asberger ◽  
Anca L. Grosu ◽  
Philipp T. Meyer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Receptor Antagonist ◽  
Disease Stage ◽  
Radiotherapy Planning ◽  
Imaging Method ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Pet Ct ◽  
Er Positive

Background: Positron emission tomography (PET)/computed tomography (CT) using the gastrin-releasing peptide receptor antagonist [68Ga]RM2 has shown to be a promising imaging method for primary breast cancer (BC) with positive estrogen receptor (ER) status. This study assessed tumor visualization by [68Ga]RM2 PET/CT in patients with pre-treated ER-positive BC and suspected metastases. Methods: This retrospective pilot study included eight female patients with initial ER-positive, pre-treated BC who underwent [68Ga]RM2 PET/CT. Most of these patients (seven out of eight; 88%) were still being treated with or had received endocrine therapy. [68Ga]RM2 PET/CTs were visually analyzed by two nuclear medicine specialists in consensus. Tumor manifestations were rated qualitatively (i.e., RM2-positive or RM2-negative) and quantitatively using the maximum standardized uptake value (SUVmax). SUVmax values were compared between the two subgroups (RM2-positive vs. RM2-negative). Results: Strong RM2 binding was found in all metastatic lesions of six patients (75%), whereas tracer uptake in all metastases of two patients (25%) was rated negative. Mean SUVmax of RM2-positive metastases with the highest SUVmax per patient (in lymph node and bone metastases; 15.8 ± 15.1 range: 3.7–47.8) was higher than mean SUVmax of the RM2-negative metastases with the highest SUVmax per patient (in bone metastases; 1.6 ± 0.1, range 1.5–1.7). Conclusions: Our data suggest that RM2 binding is maintained in the majority of patients with advanced disease stage of pre-treated ER-positive BC. Thus, [68Ga]RM2 PET/CT could support treatment decision in these patients, radiotherapy planning in oligometastatic patients or selection of patients for RM2 radioligand therapy. Further studies with larger patient cohorts are warranted to confirm these findings.

67P The role of FDG PET/CT to omit sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer

2021 ◽  
Vol 32 ◽  
pp. S50
Author(s):  
E. Tanrikulu Simsek ◽  
E. Çoban ◽  
E. Atag ◽  
S. Gungor ◽  
M. Sarı ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Neoadjuvant Chemotherapy ◽  
Lymph Node Biopsy ◽  
Node Biopsy ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1051
Author(s):  
Christopher Montemagno ◽  
Florian Raes ◽  
Mitra Ahmadi ◽  
Sandrine Bacot ◽  
Marlène Debiossat ◽  
...  
Keyword(s):  
Therapeutic Agent ◽  
Tumor Volume ◽  
Tumor Regression ◽  
Efficacy Evaluation ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Target Organs ◽  
G Protein Coupled ◽  
Complete Tumor

NeoB is a radiotracer targeting the gastrin-releasing peptide receptor (GRPR), a G-protein–coupled receptor expressed in various cancers. The aim of the present study was to evaluate the biodistribution and efficacy of this new therapeutic agent in Gastrointestinal Stromal Tumors (GIST). Eighty-two SCID mice bearing GIST-882 tumors were employed. [177Lu]Lu-NeoB biodistribution was evaluated up to seven days by organ sampling (200 pmol/0.8 MBq, i.v.). For efficacy evaluation, mice received either saline, 400 pmol or 800 pmol of [177Lu]Lu-NeoB (37MBq, 1/w, 3 w, i.v.). SPECT/CT imaging was performed at 24 h, and tumor volume was determined up to 100 days. Elevated and specific [177Lu]Lu-NeoB uptake was found in the GIST tumor, as demonstrated by in vivo competition (19.1 ± 3.9 %ID/g vs. 0.3 ± 0.1 %ID/g at 4h). [177Lu]Lu-NeoB tumor retention (half-life of 40.2 h) resulted in elevated tumor-to-background ratios. Tumor volumes were significantly reduced in both treated groups (p < 0.01), even leading to complete tumor regression at the 400 pmol dose. [177Lu]Lu-NeoB exhibited excellent pharmacokinetics with elevated and prolonged tumor uptake and low uptake in non-target organs such as pancreas. The potential of this new theragnostic agent in different indications, including GIST, is under evaluation in the FIH [177Lu]Lu-NeoB clinical trial.

Sign in / Sign up

Export Citation Format

Share Document